Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.

Richard O Phillips,Jérôme Robert, Kabiru Mohamed Abass,William Thompson,Fred Stephen Sarfo,Tuah Wilson, Godfred Sarpong, Thierry Gateau,Annick Chauty,Raymond Omollo, Michael Ochieng Otieno,Thaddaeus W Egondi,Edwin O Ampadu,Didier Agossadou,Estelle Marion,Line Ganlonon,Mark Wansbrough-Jones,Jacques Grosset, John M Macdonald,Terry Treadwell,Paul Saunderson,Albert Paintsil, Linda Lehman,Michael Frimpong, Nanaa Francisca Sarpong,Raoul Saizonou,Alexandre Tiendrebeogo,Sally-Ann Ohene,Ymkje Stienstra,Kingsley B Asiedu,Tjip S van der Werf

The Lancet（2020）

引用 65|浏览48

暂无评分

摘要

WHO with additional support from MAP International, American Leprosy Missions, Fondation Raoul Follereau France, Buruli ulcer Groningen Foundation, Sanofi-Pasteur, and BuruliVac.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要